Cosmos Health Financials - Benzinga

Cosmos Health Inc

COSMNASDAQ

Trade with Public

Trade with Public

$0.3415

0.045215.25%

Ult. Agg.: Sep 18, 9:47 AM

Panoramica Notizie Previsioni utiliDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Cosmos Health Financials

Cosmos Health (COSM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cosmos Health Reaffirms FY 2029 Guidance, Expects $200.60M Revenue, $71.20M Gross Profit, $31M Net Income, $44.20M Adjusted EBITDA

Benzinga Newsdesk

PRO
Cosmos Health Says It Projects Oliv18 To Generate Over $6M In Incremental Annual U.S. Revenue Within 12 To 18 Months

Benzinga Newsdesk

PRO
Cosmos Health Q2 EPS $(0.10) Misses $0.01 Estimate, Sales $18.986M Miss $19.420M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported

Benzinga Newsdesk

PRO
Cosmos Health Reports Preliminary Q2 Revenue Of $19.4M, Up 31.5% YoY, H1 Revenue Of $37.3M, Up ~31% YoY

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46

Benzinga Newsdesk

PRO
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a

Benzinga Newsdesk

PRO
Cosmos Health Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $17.928M Miss $21.893M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved